


## Intratumoral Administration of STING-Activating Nanovaccine Enhances T Cell Immunotherapy

Xiaoyi Jiang<sup>1,†</sup>, Jian Wang<sup>2,7,†</sup>, Xichen Zheng<sup>1</sup>, Zhida Liu<sup>6</sup>, Xinyu Zhang<sup>1</sup>, Yuwei Li<sup>1</sup>,

Jonathan Wilhelm<sup>2</sup>, Jun Cao<sup>1</sup>, Gang Huang<sup>2</sup>, Jinlan Zhang<sup>1</sup>, Baran D. Sumer<sup>4</sup>,

Jayanthi Lea<sup>5</sup>, Zhigang Lu<sup>1,3,\*</sup>, Jinming Gao<sup>2,4,\*</sup>, and Min Luo<sup>1,2,\*</sup>



- **I.T. administration of nanovaccine enhances antitumor efficacy over S.C. injection**
- **I.T. vaccination initiates the myeloid cell/CXCL9-CD8<sup>+</sup> T/IFN $\gamma$  feedback loop for T cell recruitment**